Reuters logo
BRIEF-ArQule receives clearance of IND application from the FDA for proprietary reversible BTK inhibitor, ARQ 531
April 11, 2017 / 11:22 AM / 6 months ago

BRIEF-ArQule receives clearance of IND application from the FDA for proprietary reversible BTK inhibitor, ARQ 531

April 11 (Reuters) - ArQule Inc

* ArQule receives clearance of investigational new drug application from the FDA for proprietary reversible BTK inhibitor, ARQ 531

* ArQule Inc - ArQule plans to initiate a phase 1A/B dose escalation and signal generation trial by Q3 of 2017

* ArQule - Upon completion of phase 1a trial, plans to begin phase 1B trial in number of expansion cohorts

* ArQule Inc - Expansion cohorts will include patients with C481S mutation who are refractory to other therapies Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below